Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATE: Elacestrant in ctDNA-positive ER+/HER2- Breast Cancer
NCT06923527Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Yale University. Primary endpoints: Circulating Tumor DNA Clearance and Invasive Disease-Free Survival at 18 months. Started Sep 2025; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06923527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923527.